Dietary Reference Intakes based on chronic disease endpoints: outcomes from a case study workshop for omega 3’s EPA and DHA

Given the focus on developing Dietary Reference Intakes (DRIs) based on chronic disease risk reduction and recent research for omega-3 long chain PUFA since the last DRI review, the Canadian Nutrition Society convened a panel of stakeholders for a 1-day workshop in late 2019. Attendees discussed the...

Full description

Saved in:
Bibliographic Details
Published in:Applied physiology, nutrition, and metabolism nutrition, and metabolism, 2021-05, Vol.46 (5), p.530-539
Main Authors: Racey, Megan, MacFarlane, Amanda, Carlson, Susan E, Stark, Ken D, Plourde, Mélanie, Field, Catherine J, Yates, Allison A, Wells, George, Grantham, Andrea, Bazinet, Richard P, Ma, David W.L
Format: Article
Language:English
Subjects:
acide docosahexaénoïque
acide eicosapentaénoïque
acides gras oméga-3
apports nutritionnels de référence
Cardiovascular disease
Cardiovascular diseases
Case reports
chronic disease
Chronic diseases
Chronic illnesses
Dietary Reference Intakes
Disease prevention
docosahexaenoic acid
eicosapentaenoic acid
Fish oils
Health aspects
health outcomes
Health risks
maladie cardiovasculaire
maladie chronique
naissance prématurée
Nutrition
Omega-3 fatty acids
Practice guidelines (Medicine)
pre-term birth
Risk factors
état de santé
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Given the focus on developing Dietary Reference Intakes (DRIs) based on chronic disease risk reduction and recent research for omega-3 long chain PUFA since the last DRI review, the Canadian Nutrition Society convened a panel of stakeholders for a 1-day workshop in late 2019. Attendees discussed the new NASEM guidelines for establishing DRI values based on chronic disease risk endpoints and the strength of current evidence for EPA and DHA as it relates to the new guidelines. Novelty: Summarizes evidence and expert opinions regarding the potential for reviewing DRI values for EPA and DHA and cardiovascular disease risk and early development.
ISSN:1715-5312
1715-5320
DOI:10.1139/apnm-2020-0994